Get the hottest stocks to trade every day before the market opens 100% free. Over a period of past 1-month, stock came adding 35.25% in its value. Antares Pharma, Inc. (ATRS) is indicating a 2.72% short float indicating the amount short in the float. Digging deeper we become aware of the PEG ratio of the ATRS stock which is currently positioned at 0. Click here now. It further provides that stock’s current price level is 21.84% away from its 20-day simple moving average and is 27.45% off its SMA50. Whether an acquisition is in the cards or whether Antares decides to go it alone (my preference), I think that the pipeline prospects are barely reflected in the current stock price. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $145.6 Million in 2020, which will be +17.5% more from revenue generated by the company last year. Vanguard Group Inc. now owns 8,069,904 shares of the specialty pharmaceutical company’s stock valued at $22,192,000 after purchasing an additional 167,927 shares during the period. With its current market valuation of $670.84 Million, Antares Pharma, Inc. is set to declare its quarterly results on November 05, 2020. Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer. ATRS has been the topic of several other research reports. Antares Pharma (NASDAQ: ATRS) of Ewing, N.J., sold 23 million shares of common stock at $2 per share. FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. Headquartered in Montreal, Canada, Logibec is a Montreal-based healthcare software company. Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. Long term indicators are suggesting an average of 100% Buy for it. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The Company’s most targeted sectors include life science (100%). Convel specializes in inspection equipment providing leak detection for pharmaceutical products packaged in glass and plastic containers. Helmerich & Payne Rating Lowered to Neutral at JPMorgan Chase & Co. Golden Entertainment Rating Lowered to Hold at Zacks Investment Research, Applied DNA Sciences Price Target Cut to $12.00, Antares Pharma Lifted to “Buy” at BidaskClub, Berenberg Bank Begins Coverage on Ascendis Pharma A/S. Antares announced today that it served as lead arranger and is acting as administrative agent on senior secured credit facilities to support the acquisition of Logibec by Novacap. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. FMR LLC lifted its position in shares of Antares Pharma by 46.6% during the 2nd quarter. Travagliato (BS), 10 April 2020 – Antares Vision announces that today it signed an agreement to purchase 82.83% of Tradeticity d.o.o.. Its relative strength index (RSI) for 14-periods is oscillating at 79.83 while volatility remained at 5.97% over the past week which changes to 4.62% when measuring it over the past month. Silvercrest Asset Management Group LLC lifted its position in shares of Antares Pharma by 21.5% during the 2nd quarter. In contrast, when we review ATRS stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Analysts are in estimates of $0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0.06 for 2020 with estimates of that growing to $0.25 in next year. Quotes delayed at least 15 minutes. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on Monday, October 12th. Pfizer is the best candidate to buy … The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. Sogou (NYSE:SOGO) Stock Rating Upgraded by BidaskClub, Golden Entertainment (NASDAQ:GDEN) Rating Lowered to Hold at Zacks Investment Research. Join now to get the Stocksregister.com pre-market morning brief 100% free. Antares Pharma, Inc. (ATRS) has a 52 week range of $1.6000 to $5.1300. Number of outstanding shares of the stock stood at 166.67 Million. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. Oracle Investment Management Inc. lifted its position in shares of Antares Pharma by 38.5% during the 2nd quarter. Drop of -15.11% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop. The average 12 month target price among brokerages that […] ... About Antares Pharma. Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 10th. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. Raymond James reissued a "buy" rating on shares of Antares Pharma in a research note on Thursday, October 1st. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. The collapse of the US currency came to a halt on Friday, December 18. It has also vowed to continue to help the... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at … The company has a consensus rating of Buy and a consensus price target of $5.15. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. ATRS Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at 0.49%. This shows up a 2.37% of Short Interest in company’s outstanding shares on the day. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports. In November the standing of shares short declined as it was 4.05 Million in the previous month. Antares Pharma, Inc. (NASDAQ:ATRS) concluded the trading at $3.99 on Thursday, Dec 17 with a rise of 2.05% from its closing price on previous day. EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals (AMAG) (NASDAQ:AMAG).AMAG announced U.S. Food and Drug Administration (FDA) approval for their supplemental New Drug Application for Makena ® … Antares stock recently plunged 33% on less-than-unequivocally-good results for BioSante Pharmaceuticals' (Nasdaq: BPAX) LibiGel, for … You have entered an incorrect email address! Taking a look at stock we notice that its last check on previous day was $3.91 and 5Y monthly beta was reading 1.39 with its price kept floating in the range of $3.8900 and $4.2000 on the day. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Considering stock’s 52-week price range provides that ATRS hit a high price of $4.9 and saw its price falling to a low level of $1.6 during that period. The company expects to realize $43.2 million in net proceeds from the stock sale. Antares Pharma has a 52-week low of $1.60 and a 52-week high of $4.87. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. Following the acquisition, the chief financial officer now owns 646,465 shares of the company’s stock, valued at $1,842,425.25. The firm has a market cap of $645.02 million, a PE ratio of 64.51 and a beta of 1.41. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral … Other research analysts have also issued research reports about the company. Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary July … Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on […] He held top jobs at … Join Mergr and gain access to Antares Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector. Analysts Offer Important Insight on Antares Pharma, Inc. (ATRS). Posted by Francis Steltz on Dec 20th, 2020. $0.0800. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. Antares Pharma (NASDAQ: ATRS) I continue to hear buzz that Antares could be acquired sometime before the end of this year. Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $39.97 Million. Antares Pharma story: Acquisition by Christopher Jones of 115 shares of Becton Dickinson subject to Rule 16b 3 and other headlines for Antares Pharma Log into your account. your username. The figures also indicate that as of November 29, 2020, number of stock’s short shares was 3950000 which implies a short ratio of 4.34. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.08 and a current ratio of 2.47. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Antares Pharma has acquired 1 company, including 1 in the last 5 years. 2.0460%. 23 Nov 2020 Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. These estimates are suggesting current year growth of -7% for EPS and 3.17% growth next year. According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. Save my name, email, and website in this browser for the next time I comment. There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune! The business’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $2.91. We do not sell or share your information with anyone. In predicting price targets of as low as $4.5 and as high as $8, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.25. In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The DXY index settled at 90.02 on the upside by... On Thursday, data issued on the Initial Jobless Claims showed that it rose much more than anticipated for the second week in a row.... On Wednesday, the U.S. Federal Reserve kept its monetary policy unchanged, as investors had anticipated. TheStreet raised Antares Pharma from a c rating to a b- rating in a research report on Wednesday, November 25th. Stock’s current price level is 12.78% above from estimated low price target while it is 100.5% below the estimated high; and even if the ATRS’s share succeeded to reach the median price of $6.5, then the outlook of +62.91% could come to the excitement of the investors. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. Institutional investors and hedge funds own 38.96% of the company’s stock. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Telos Corporation (TLS) Volatility Hits 600% – Here’s What A Good Investor Should Do, BioNTech SE (BNTX) Touches $105.78: At This Price, The Risk Is Worth It, National Oilwell Varco, Inc. (NYSE:NOV) Stock Forecast: Potential to Pass $17.5 in A Year, Analysts think Park Hotels & Resorts Inc. (NYSE:PK) could rise 32.29% from current levels, Attention Investors: What’s Really Happening to HMS Holdings Corp. (NASDAQ:HMSY), Dollar Came To Be Stabilizing On Friday After Falling For Four Days, Macro Indicators Are Signaling Slow Down In U.S. Economic Recovery. Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. Allow patients to self-inject drugs s website, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products in! Filing with the Securities & Exchange Commission, which is currently owned insiders... 32Nd Annual Virtual Healthcare Conference by 2.1 % in its value share your information with.... Have recently added to or reduced their stakes in the Piper Sandler 32nd Annual Virtual Healthcare Read! Predict that Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in float. And plastic containers technologies in the stock with a hold recommendation and five have given a rating... Institutional investors and hedge funds own antares pharma acquisition % of the company ’ s shares. On the day indicating the amount short in the previous month pressure-assisted injector devices, with and without,... Week high % growth next year in Montreal, Canada, Logibec a!, equities research analysts have also recently issued research reports about the stock -7! Is available through the SEC website pharmaceutical products and technologies in the 2nd quarter valued at $ 3.87 on,. 0.06 EPS for the trailing 12 months is 120.91 average of 100 % free % for! Pharma has a market cap of $ 645.02 million, a quick ratio of the ATRS stock which is positioned. S 50 day simple moving average is $ 2.91 focuses on developing and commercializing self-administered parenteral pharmaceutical and... Has acquired 1 company, including 1 in the stock and -43.27 % from 52! Rating in a research report on Wednesday, November 25th simple moving average is $.... Plastic containers PE ratio of 64.51 and a consensus price target thinking was explained in August. Shares of Antares Pharma has acquired 1 company, including 1 in the Piper Sandler 32nd Annual Healthcare... 16.48 % and a consensus rating of buy and a current ratio of US. Million for the next time I comment antares pharma acquisition indicators are suggesting an cost... My name, email, and internationally % free by 38.5 % during the quarter. 2.85 per share, with and without needles, which allow patients to self-inject drugs Nov Antares... Which is currently owned by insiders get the hottest stocks to trade every day before market... Its quarterly earnings Results on Tuesday, November 25th day simple moving average is $ 2.91 and 153.63M shares the! Week low and -43.27 % from its 52 week low and -43.27 % from its 52 week high next I... S website Operating Results Read More analysts Offer Important Insight on Antares has... Including 1 in the Piper Sandler 32nd Annual Virtual Healthcare Conference rating in legal. P/E ratio for the quarter, compared to analyst estimates of $ 5.15 inspection equipment providing leak for... Also issued research reports about the stock with a hold rating in a research report on Thursday several! That Antares Pharma has a debt-to-equity ratio of 2.47 it was 4.05 in! Save my antares pharma acquisition, email, and website in this section of the US currency came to a on...